Pharmacelsus (member of GBA Group Pharma) is proud to announce that again we have been rewarded with the CIR confirmation for research and innovation. We are very honored that our scientific research has been proofed and recognized with this certificate. This authorization granted by the French Ministry of Higher Education, Research and Development is valid for the years 2021, 2022 and 2023 and was first granted to Pharmacelsus in 2015.

Pharmacelsus, one of Germany´s market-leading early stage CRO, plans, organizes and realizes customized preclinical studies for more than 20 years. Our assays meet national and international regulatory demands while using a unique consultative approach to serve more than 120+ satisfied customers who rely on Pharmacelsus’ expertise, experience and passion for science.

Contact us:

Pharmacelsus GmbH

Science Park 2
66123 Saarbrücken
Germany

Tel. +49 681 3946 - 7510
Fax +49 681 3946 - 7511

info@pharmacelsus.com